Sprint Bioscience AB's quarterly market cap
increased
from Sep. 2025 (kr60.8 Mil) to Dec. 2025 (kr155.1 Mil) and
increased
from Dec. 2025 (kr155.1 Mil) to Mar. 2026 (kr251.1 Mil).
Sprint Bioscience AB's annual market cap
declined
from Dec. 2023 (kr121.1 Mil) to Dec. 2024 (kr110.5 Mil) but then
increased
from Dec. 2024 (kr110.5 Mil) to Dec. 2025 (kr155.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sprint Bioscience AB's Enterprise Value for Today is kr321.1 Mil.
Sprint Bioscience AB (OSTO:SPRINT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sprint Bioscience AB Market Cap Related Terms
Sprint Bioscience AB Market Cap Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sprint Bioscience AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a Market Cap of kr429.4 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #926 out of 1426 companies in the Biotechnology industry, placing it in the top 64.9%.
Is Sprint Bioscience AB's Market Cap too high?
Sprint Bioscience AB's current Market Cap is kr429.4 Mil. Based on the distribution chart, Sprint Bioscience AB ranks #926 out of 1426 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #926 out of 1426 companies for Market Cap. This places Sprint Bioscience AB in the lower half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Market Cap is kr429.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.07 — trading 86.7% above its estimated fair value. The current Market Cap is kr429.4 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Market Cap is kr429.4 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.07 is trading 86.7% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
Market Cap: kr429.4 Mil
GF Value™: kr2.18 vs. price of kr4.07 (86.7% above fair value)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
